CompanyXRTXNasdaqVancouver, A1

XORTX Therapeutics Inc.

XORTX develops small-molecule therapies targeting purine metabolism and xanthine oxidase.

6-KSep 18Latest SEC filing, period to Sep 18

Sep 10Latest story

September 2026

Sep 10Regulatory decisionXORTX Therapeutics Inc.

August 2026